Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche lamifiban/heparin arm shows 30% decrease in death/MI at six months; no effect seen at 30-day endpoint.

Executive Summary

ROCHE LAMIFIBAN PLUS HEPARIN REDUCES DEATH/MI INCIDENCE 30% AT SIX MONTHS, F. Van de Werf, University Hospital (Leuven, Belgium), said during a symposium on glycoprotein IIb/IIIa receptor antagonists in unstable angina at the European Society of Cardiology meeting in Stockholm Aug. 25. A combination of 300 mcg lamifiban with heparin produced a "statistically significant 30% reduction" of death or myocardial infarction in unstable angina patients, Van de Werf stated.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts